Evidence map›Paper›PMID 36407646›Full record

ArticleSkin appendage disorders2022

Successful Response to a Combination of Intralesional Methotrexate and Fractional CO

Ana Rodríguez-Villa Lario, Ángel Aguado-García, Juan José Andrés-Lencina, Cristina Corredera, Marta García-Legaz Martínez, Ricardo M Alonso de Celada, Daniela Subiabre-Ferrer, Cristian Valenzuela-Oñate, José María Ricart-Vayá, Alba Gómez-Zubiaur

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in Skin appendage disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Ana Rodríguez-Villa LarioTrichology Unit, Instituto Médico Ricart, Hospital Ruber Internacional, Grupo Quirónsalud, Madrid, Spain.
Ángel Aguado-GarcíaTrichology Unit, Instituto Médico Ricart, Hospital Quirónsalud Valencia, Valencia, Spain.
Juan José Andrés-LencinaTrichology Unit, Instituto Médico Ricart, Hospital Quirónsalud Valencia, Valencia, Spain.
Cristina CorrederaTrichology Unit, Instituto Médico Ricart, Hospital Quirónsalud Valencia, Valencia, Spain.
Marta García-Legaz MartínezTrichology Unit, Instituto Médico Ricart, Hospital Quirónsalud Valencia, Valencia, Spain.
Ricardo M Alonso de CeladaTrichology Unit, Instituto Médico Ricart, Hospital Ruber Internacional, Grupo Quirónsalud, Madrid, Spain.
Daniela Subiabre-FerrerTrichology Unit, Instituto Médico Ricart, Hospital Quirónsalud Valencia, Valencia, Spain.
Cristian Valenzuela-OñateTrichology Unit, Instituto Médico Ricart, Hospital Quirónsalud Valencia, Valencia, Spain.
José María Ricart-VayáTrichology Unit, Instituto Médico Ricart, Hospital Ruber Internacional, Grupo Quirónsalud, Madrid, Spain.
Alba Gómez-ZubiaurTrichology Unit, Instituto Médico Ricart, Hospital Ruber Internacional, Grupo Quirónsalud, Madrid, Spain.
Hospital Ruber Internacional · ESHospital Universitario Príncipe de Asturias · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Refractory cases of alopecia areata (AA) may be considered a therapeutic challenge. Intralesional methotrexate (IL-MTX) has been used in other dermatological diseases rather than AA. Likewise, its topical use as an immunosuppressant drug may be of interest for the control of the lymphoid infiltrate in AA. On the other hand, the use of fractional ablative laser is supported in literature as an alternative or complementary treatment in AA, whilst the generation of columns of thermal damage may favour the migration of cells and cytokines that are beneficial. Case Presentation: In this paper, we present 2 cases in which IL-MTX and ablative fractional CO Conclusion: Previous research encompasses a total of 23 patients. Most patients presented with patchy AA. The doses administered ranged from 2.5 to 50 mg with an average frequency of 3 weeks. On average, most patients required a minimum of 3 sessions. One case employed 1% topical methotrexate ointment. Adverse local events were mild and transient. In conclusion, the concomitant application of these treatments has not been reported previously. Specific recommendations relating to the appropriate dosing of the drug, frequency of administration, and requirements for analytical control studies should be determined in further studies.

Indexed as

Ablative laserAlopecia areataCO2Drug assisted deliveryIntralesional methotrexateLaserMesotherapyMethotrexate

Identifiers

PMID36407646
PMCPMC9672868
OpenAlexW4281492760

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.